BISTIM研究:双卵巢刺激(duostim)与两次常规卵巢刺激在接受体外受精的卵巢反应不良患者中的随机对照试验
这项多中心开放标签随机对照试验纳入88例卵巢反应不良(POR)患者,比较同一周期内双卵巢刺激(duostim)与连续两个拮抗剂方案周期的效果。结果显示两组获卵总数无统计学差异(对照组4.6 vs duostim组5.0,P=0.56),duostim未显示获益。
要点
- 在POR患者中,duostim与连续两个拮抗剂周期的累计获卵数无统计学差异。
- 对照组移植胚胎总数显著高于duostim组(1.5 vs 0.9,P=0.03)。
- duostim组第二次取卵时间显著短于对照组(0.3 vs 2.8个月,P<0.001)。
核心结论
- 在卵巢反应不良(POR)患者中,duostim与连续两个拮抗剂周期相比,累计获卵总数和成熟卵母细胞数无统计学差异(P=0.56)。
- duostim未显示在获卵数方面的获益,且冻融策略增加卵母细胞/胚胎浪费风险。
- duostim唯一益处是将第二次取卵时间缩短约2周。
研究设计与样本
- 多中心、开放标签随机对照试验,于2018年9月至2021年3月在四个IVF中心进行。
- 纳入88例POR患者(采用调整的博洛尼亚标准:窦卵泡计数≤5和/或抗苗勒管激素≤1.2 ng/ml),duostim组44例,常规对照组44例。
- 主要结局为两个周期的累计获卵数;样本量计算基于优效性假设,把握度0.8、α风险0.05、取消率35%,每组需44例。
主要发现
- 两组累计获卵数均值(标准差):对照组4.6(3.4)vs duostim组5.0(3.4),平均差+0.4(95%CI -1.1至1.9),P=0.56。
- 每组患者移植胚胎总数:对照组1.5(1.1)vs duostim组0.9(1.1),P=0.03。
- 两个累计周期后至少一次胚胎移植的比例:对照组78% vs duostim组53.8%,P=0.02。
- 第二次取卵时间:对照组2.8(1.3)个月 vs duostim组0.3(0.5)个月,P<0.001。
- 累计活产率:对照组34.1% vs duostim组17.9%,P=0.08,无统计学差异。
临床怎么用
- 在常规实践中,duostim对POR患者在新鲜胚胎移植方面的获益未在本随机对照试验中得到证实。
- duostim似乎对女性是安全的;但两次冻融过程是强制性的,增加卵母细胞/胚胎浪费风险。
- duostim唯一益处是在需要累积卵母细胞/胚胎时,将第二次取卵时间缩短约2周。
局限性
- 该随机对照试验受到冠状病毒病2019大流行影响,IVF活动中断10周;延迟已重新计算以排除该时期,但duostim组一名女性无法进行黄体期刺激。
- 两组均出现意外良好的卵巢反应和第一次取卵后妊娠,对照组发生率更高。
- 本研究仅针对累计获卵数进行把握度计算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is the total number of oocytes retrieved with dual ovarian stimulation in the same cycle (duostim) higher than with two consecutive antagonist cycles in poor responders? SUMMARY ANSWER: Based on the number of total and mature oocytes retrieved in women with poor ovarian response (POR), there is no benefit of duostim versus two consecutive antagonist cycles. WHAT IS KNOWN ALREADY: Recent studies have shown the ability to obtain oocytes with equivalent quality from the follicular and the luteal phase, and a higher number of oocytes within one cycle when using duostim. If during follicular stimulation smaller follicles are sensitized and recruited, this may increase the number of follicles selected in the consecutive luteal phase stimulation, as shown in non-randomized controlled trials (RCT). This could be particularly relevant for women with POR. STUDY DESIGN, SIZE, DURATION: This is a multicentre, open-labelled RCT, performed in four IVF centres from September 2018 to March 2021. The primary outcome was the number of oocytes retrieved over the two cycles. The primary objective was to demonstrate in women with POR that two ovarian stimulations within the same cycle (first in the follicular phase, followed by a second in the luteal phase) led to the retrieval of 1.5 (2) more oocytes than the cumulative number of oocytes from two consecutive conventional stimulations with an antagonist protocol. In a superiority hypothesis, with power 0.8 alpha-risk 0.05 and a 35% cancellation rate, 44 patients were needed in each group. Patients were randomized by computer allocation. PARTICIPANTS/MATERIALS, SETTING, METHODS: Eighty-eight women with POR, defined using adjusted Bologna criteria (antral follicle count ≤5 and/or anti-Müllerian hormone ≤1.2 ng/ml) were randomized, 44 in the duostim group and 44 in the conventional (control) group. HMG 300 IU/day with flexible antagonist protocol was used for ovarian stimulation, except in luteal phase stimulation of the duostim group. In the duostim group, oocytes were pooled and inseminated after the second retrieval, with a freeze-all protocol. Fresh transfers were performed in the control group, frozen embryo transfers were performed in both control and duostim groups in natural cycles. Data underwent intention-to-treat and per-protocol analyses. MAIN RESULTS AND THE ROLE OF CHANCE: There was no difference between the groups regarding demographics, ovarian reserve markers, and stimulation parameters. The mean (SD) cumulative number of oocytes retrieved from two ovarian stimulations was not statistically different between the control and duostim groups, respectively, 4.6 (3.4) and 5.0 (3.4) [mean difference (MD) [95% CI] +0.4 [-1.1; 1.9], P = 0.56]. The mean cumulative numbersof mature oocytes and total embryos obtained were not significantly different between groups. The total number of embryos transferred by patient was significantly higher in the control group 1.5 (1.1) versus the duostim group 0.9 (1.1) (P = 0.03). After two cumulative cycles, 78% of women in the control group and 53.8% in the duostim group had at least one embryo transfer (P = 0.02). There was no statistical difference in the mean number of total and mature oocytes retrieved per cycle comparing Cycle 1 versus Cycle 2, both in control and duostim groups. The time to the second oocyte retrieval was significantly longer in controls, at 2.8 (1.3) months compared to 0.3 (0.5) months in the duostim group (P < 0.001). The implantation rate was similar between groups. The cumulative live birth rate was not statistically different, comparing controls versus the duostim group, 34.1% versus 17.9%, respectively (P = 0.08). The time to transfer resulting in an ongoing pregnancy did not differ in controls 1.7 (1.5) months versus the duostim group, 3.0 (1.6) (P = 0.08). No serious adverse events were reported. LIMITATIONS, REASONS FOR CAUTION: The RCT was impacted by the coronavirus disease 2019 pandemic and the halt in IVF activities for 10 weeks. Delays were recalculated to exclude this period; however, one woman in the duostim group could not have the luteal stimulation. We also faced unexpected good ovarian responses and pregnancies after the first oocyte retrieval in both groups, with a higher incidence in the control group. However, our hypothesis was based on 1.5 more oocytes in the luteal than the follicular phase in the duostim group, and the number of patients to treat was reached in this group (N = 28). This study was only powered for cumulative number of oocytes retrieved. WIDER IMPLICATIONS OF THE FINDINGS: This is the first RCT comparing the outcome of two consecutive cycles, either in the same menstrual cycle or in two consecutive menstrual cycles. In routine practice, the benefit of duostim in patients with POR regarding fresh embryo transfer is not confirmed in this RCT: first, because this study demonstrates no improvement in the number of oocytes retrieved in the luteal phase after follicular phase stimulation, in contrast to previous non-randomized studies, and second, because the freeze-all strategy avoids a pregnancy with fresh embryo transfer after the first cycle. However, duostim appears to be safe for women. In duostim, the two consecutive processes of freezing/thawing are mandatory and increase the risk of wastage of oocytes/embryos. The only benefit of duostim is to shorten the time to a second retrieval by 2 weeks if accumulation of oocytes/embryos is needed. STUDY FUNDING/COMPETING INTERESTS: This is an investigator-initiated study supported by a research Grant from IBSA Pharma. N.M. declares grants paid to their institution from MSD (Organon France); consulting fees from MSD (Organon France), Ferring, and Merck KGaA; honoraria from Merck KGaA, General Electrics, Genevrier (IBSA Pharma), and Theramex; support for travel and meetings from Theramex, Merck KGaG, and Gedeon Richter; and equipment paid to their institution from Goodlife Pharma. I.A. declares honoraria from GISKIT and support for travel and meetings from GISKIT. G.P.-B. declares Consulting fees from Ferring and Merck KGaA; honoraria from Theramex, Gedeon Richter, and Ferring; payment for expert testimony from Ferring, Merck KGaA, and Gedeon Richter; and support for travel and meetings from Ferring, Theramex, and Gedeon Richter. N.C. declares grants from IBSA pharma, Merck KGaA, Ferring, and Gedeon Richter; support for travel and meetings from IBSA pharma, Merck KGaG, MSD (Organon France), Gedeon Richter, and Theramex; and participation on advisory board from Merck KGaA. E.D. declares support for travel and meetings from IBSA pharma, Merck KGaG, MSD (Organon France), Ferring, Gedeon Richter, Theramex, and General Electrics. C.P.-V. declares support for travel and meetings from IBSA Pharma, Merck KGaA, Ferring, Gedeon Richter, and Theramex. M.Pi. declares support for travel and meetings from Ferring, Gedeon Richetr, and Merck KGaA. M.Pa. declares honoraria from Merck KGaA, Theramex, and Gedeon Richter; support for travel and meetings from Merck KGaA, IBSA Pharma, Theramex, Ferring, Gedeon Richter, and MSD (Organon France). H.B.-G. declares honoraria from Merck KGaA, and Gedeon Richter and support for travel and meetings from Ferring, Merck KGaA, IBSA Pharma, MSD (Organon France), Theramex, and Gedeon Richter. S.G. and M.B. have nothing to declare. TRIAL REGISTRATION NUMBER: Registration number EudraCT: 2017-003223-30. ClinicalTrials.gov identifier: NCT03803228. TRIAL REGISTRATION DATE: EudraCT: 28 July 2017. ClinicalTrials.gov: 14 January 2019. DATE OF FIRST PATIENT’S ENROLMENT: 3 September 2018.
引用
- Massin N, Abdennebi I, Porcu-Buisson G, et al. The BISTIM study: a randomized controlled trial comparing dual ovarian stimulation (duostim) with two conventional ovarian stimulations in poor ovarian responders undergoing IVF. Hum Reprod. 2023. PMID: 36864699. doi:10.1093/humrep/dead038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。